Study guide

9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies

Key Takeaways Explain This Topic AI

The multimodal analgesia paradigm combines pharmacological and non-pharmacological interventions targeting distinct neurobiological pain pathways to achieve synergistic pain relief while minimizing opioid exposure.

Systemic NSAIDs carry significant gastrointestinal, cardiovascular, and renal toxicities, and are strictly contraindicated in advanced chronic kidney disease (CKD stage 3b-5) and active peptic ulcer disease.

Acetaminophen requires strict daily dosing limits (maximum 3,000–4,000 mg/day in healthy adults; maximum 2,000 mg/day or avoidance in chronic alcohol use disorder or hepatic impairment).

Gabapentinoids (gabapentin, pregabalin) act on alpha-2-delta voltage-gated calcium channel subunits; when combined with opioids, they produce synergistic respiratory depression and carry documented misuse liability.

Low-dose buprenorphine formulations (transdermal Butrans patch and buccal Belbuca film) are specifically FDA-approved for chronic pain, offering potent analgesia with a ceiling effect on respiratory depression, lack of end-organ toxicity, and reduced hyperalgesia compared to full agonists.

Last updated: September 2026

9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must design and implement comprehensive multimodal pain management regimens that harness synergistic non-opioid pharmacotherapy, low-dose chronic pain buprenorphine formulations, targeted interventional procedures, and evidence-based behavioral therapies to optimize functional recovery and mitigate substance-related harms.

1. The Multimodal Analgesia Paradigm

Pain neurobiology involves a complex four-stage neurophysiological pathway: transduction (conversion of noxious stimuli into action potentials by nociceptors), transmission (propagation along A-delta and C primary afferent fibers to the dorsal horn of the spinal cord), modulation (inhibition or amplification of nociceptive signals via descending monoaminergic pathways), and perception (processing within the somatosensory cortex, insula, and limbic structures). Multimodal Pain Pathway Targeting:

  • [Noxious Stimulus: Tissue Injury / Inflammation]
  • │
  • ▼ (Transduction)
  • [Peripheral Nociceptors] ──> Blocked by: NSAIDs, Acetaminophen, Topical Lidocaine
  • │
  • ▼ (Transmission)
  • [Primary Afferent Axon] ──> Blocked by: Local Anesthetics, Peripheral Nerve Blocks
  • │
  • ▼ (Synaptic Relay at Dorsal Horn)
  • [Substantia Gelatinosa] ──> Modulated by: Gabapentinoids (Alpha-2-Delta Ligands),
  • │ Epidural Injections, Spinal Cord Stimulation
  • ▼ (Modulation via Descending Pathways)
  • [Brainstem Monoaminergic]──> Enhanced by: SNRIs (Duloxetine), TCAs (Nortriptyline),
  • │ Buprenorphine (Mu Agonism / Kappa Antagonism)
  • ▼ (Perception)
  • [Cortex & Limbic System] ──> Mitigated by: CBT-CP, ACT, MBSR, Biofeedback

By combining therapeutic modalities that act on distinct molecular targets and anatomical levels of this neuroaxis, the APRN achieves additive or synergistic analgesia . This multimodal approach substantially lowers required doses of individual medications, mitigates single-agent toxicities, produces superior functional improvement, and minimizes or completely eliminates reliance on full mu-opioid agonist analgesics.

  • 2. Comprehensive Non-Opioid Pharmacotherapy
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs inhibit the cyclooxygenase enzymes ( COX-1 and COX-2 ), blocking the conversion of arachidonic acid into pro-inflammatory prostaglandins and thromboxanes.

NSAID Subclass Examples Mechanism & Selectivity Primary Toxicities & Contraindications

Non-Selective NSAIDs Ibuprofen, Naproxen, Ketorolac, Indomethacin Inhibit both COX-1 (homeostatic gastric mucosa, platelet aggregation) and COX-2 (inflammatory prostaglandins). Gastrointestinal: Mucosal ulceration, perforation, upper GI bleeding.; Renal: Afferent arteriolar vasoconstriction, acute kidney injury (AKI), hyperkalemia, sodium/fluid retention.; Contraindicated: Active peptic ulcer disease, CKD stage 3b–5 (eGFR <45 mL/min), decompensated cirrhosis.

COX-2 Selective Inhibitors Celecoxib, Meloxicam (preferential) Selectively inhibit COX-2 inducible inflammatory enzyme while sparing homeostatic COX-1 gastric protection. Cardiovascular: Increased risk of myocardial infarction, thrombotic stroke, and worsening hypertension due to suppression of endothelial prostacyclin without inhibiting platelet thromboxane A2.; Boxed Warning: Contraindicated in post-CABG surgery setting; avoid in severe cardiovascular disease.

Advanced Practice Consideration: In patients with moderate renal impairment or high gastrointestinal bleeding risk where an oral NSAID is contemplated, adding a proton pump inhibitor (PPI) or misoprostol reduces gastric ulceration, but does not protect against renal afferent arteriolar vasoconstriction or cardiovascular thrombotic events.

Acetaminophen (Paracetamol / APAP)

Mechanism: Acts primarily within the central nervous system to inhibit prostaglandin synthesis (via central COX variants), activate descending serotonergic inhibitory pathways, and modulate the cannabinoid receptor/TRPV1 system. It lacks peripheral anti-inflammatory activity.

Dosing Thresholds: Standard maximum daily dose is 3,000 mg to 4,000 mg/day in healthy adults.

Hepatotoxicity Cautions: In patients with chronic alcohol use disorder , pre-existing hepatic disease, malnourishment, or cirrhosis, daily dosing must be restricted to a maximum of 2,000 mg/day or avoided entirely. Chronic alcohol consumption induces CYP2E1, which accelerates the conversion of acetaminophen into its highly toxic, reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) . Concurrently, chronic alcohol use depletes intracellular glutathione stores, preventing hepatic detoxification of NAPQI and triggering centrilobular hepatic necrosis.

Gabapentinoids (Gabapentin, Pregabalin)

Mechanism: Structural analogues of gamma-aminobutyric acid (GABA) that do not bind to GABA-A or GABA-B receptors. Instead, they selectively bind to the alpha-2-delta-1 ( α 2 δ − 1 \alpha_2\delta-1 α 2 ​ δ − 1 ) auxiliary subunit of presynaptic voltage-gated calcium channels in the spinal dorsal horn, reducing calcium influx and attenuating the exocytotic release of excitatory neurotransmitters (glutamate, substance P, calcitonin gene-related peptide [CGRP]).

Indications: Diabetic peripheral neuropathy, post-herpetic neuralgia, radiculopathy, central neuropathic pain, and fibromyalgia.

Pharmacokinetic Differences:

Gabapentin: Undergoes saturable, non-linear L-type amino acid transporter absorption in the small intestine (bioavailability drops from 60% at 300 mg to <35% at 1,600 mg). Requires gradual titration up to 1,800–3,600 mg/day in divided doses (TID).

Pregabalin: Rapid, linear, dose-proportional absorption with >90% bioavailability. Dosing ranges from 150 to 600 mg/day in divided doses (BID or TID).

Renal Clearance: Both agents are cleared entirely unmetabolized by renal excretion; dosing must be adjusted strictly according to creatinine clearance.

Abuse Liability & Synergistic Respiratory Depression: In 2019, the FDA issued a safety warning regarding serious breathing difficulties when gabapentinoids are co-prescribed with opioids or in patients with underlying respiratory impairment. In individuals with substance use disorders, gabapentinoids possess documented misuse potential—frequently co-ingested with opioids to amplify euphoria, self-manage withdrawal, or induce sedation. Pregabalin is a federally controlled Schedule V substance; multiple states now classify gabapentin as a controlled substance and track it in state PDMPs.

Antidepressant Analgesics: SNRIs and TCAs

Drug Class Common Agents Primary Analgesic Mechanism Clinical Indications Key Adverse Effects & Monitoring

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Duloxetine, Milnacipran, Venlafaxine Potent inhibition of presynaptic reuptake of norepinephrine and serotonin, reinforcing descending monoaminergic pain inhibition. Diabetic peripheral neuropathy, fibromyalgia, chronic low back pain, osteoarthritis. Nausea, hyperhidrosis, dry mouth, dose-dependent blood pressure elevation. Avoid in severe hepatic impairment or severe renal impairment (eGFR <30 mL/min).

Tricyclic Antidepressants (TCAs) Amitriptyline, Nortriptyline, Desipramine Non-selective reuptake inhibition of norepinephrine > serotonin, plus sodium channel and NMDA receptor blockade. Post-herpetic neuralgia, diabetic neuropathy, migraine prophylaxis, fibromyalgia. Anticholinergic: Dry mouth, urinary retention, severe constipation, blurred vision.; Cardiac Toxicity: Prolongation of cardiac QTc interval, fatal ventricular arrhythmias in overdose.; Contraindicated: Conduction defects, recent MI.

Topical Analgesics: Localized Relief Without Systemic Toxicity

Topical Lidocaine 5% (Patch or Ointment): Binds to and blocks voltage-gated sodium channels ( N a V Na_V N a V ​ ) on hyperactive, damaged cutaneous nociceptors, preventing generation of aberrant action potentials. Indicated for localized neuropathic pain (e.g., post-herpetic neuralgia). Applied for up to 12 hours on, followed by 12 hours off to avoid tachyphylaxis and systemic absorption. Systemic absorption is negligible (<3%–5%), rendering it exceptionally safe in elderly or medically frail patients.

Topical Diclofenac (1% Gel, 1.3% Patch, 2% Solution): Provides localized inhibition of COX-2 enzymes within superficial synovial structures and subcutaneous tissues. Highly effective for knee and hand osteoarthritis. Systemic exposure is only 6% compared to oral diclofenac, dramatically reducing risks of gastrointestinal ulceration and systemic nephrotoxicity.

3. Low-Dose Buprenorphine Formulations Indicated for Chronic Pain

Buprenorphine is widely recognized as a mainstay for Opioid Use Disorder (OUD) at high sublingual doses (8 mg to 24 mg/day). However, distinct low-dose microgram formulations are specifically approved and indicated for the management of severe, daily, around-the-clock chronic pain. Buprenorphine Formulations: Pain vs. OUD Dosing Continuum:

  • [Chronic Pain Formulations (Micrograms)] [OUD Formulations (Milligrams)]
  • ┌─────────────────────────────────────────┐ ┌───────────────────────────────────┐
  • │ Butrans Transdermal: 5 to 20 mcg/hour │ │ Suboxone SL Film: 2 mg to 24 mg/d │
  • │ Belbuca Buccal Film: 75 to 900 mcg q12h │ │ Zubsolv SL Tablet: 1.4 to 11.4 mg/d│
  • └─────────────────────────────────────────┘ └───────────────────────────────────┘
  • (Dosed in MICROGRAMS to target analgesia) (Dosed in MILLIGRAMS to achieve
  • 85%+ mu-opioid receptor blockade)
  • Formulations, Strengths, and Administration

Transdermal Patch (Butrans): Strengths: 5, 7.5, 10, 15, and 20 mcg/hour . Applied to intact skin (upper arm, chest, upper back) once every 7 days . Doses exceeding 20 mcg/hour are not recommended due to potential QTc interval prolongation.

Buccal Film (Belbuca): Strengths: 75, 150, 300, 450, 600, 750, and 900 mcg . Placed on the inner cheek mucosa and allowed to dissolve completely, dosed every 12 hours .

Clinical and Pharmacological Advantages Over Full Agonist Opioids

Ceiling on Respiratory Depression: Buprenorphine's partial mu agonism recruits G-protein signaling while causing minimal downstream beta-arrestin-2 activation, creating a therapeutic plateau that dramatically lowers fatal overdose risk.

Reduced Hyperalgesia (Anti-Dynorphin Effect): Full mu agonists chronically upregulate dynorphin and spinal neuroinflammation, leading to opioid-induced hyperalgesia (OIH) . Buprenorphine acts as a potent kappa-opioid receptor antagonist , preventing OIH and stabilizing affective pain pathways.

Absence of End-Organ Immunosuppression and Hypogonadism: Unlike morphine and methadone, buprenorphine does not suppress the hypothalamic-pituitary-gonadal (HPG) axis, preserving normal testosterone and estrogen levels, preventing opioid-induced androgen deficiency (OPIAD), and sparing immune function.

Renal and Hepatic Safety: Buprenorphine undergoes hepatic glucuronidation (UGT1A1) and CYP3A4 metabolism to norbuprenorphine, followed primarily by fecal elimination (70%–80%). Only 10%–20% is eliminated renally. No dose adjustment is required in mild-to-moderate renal impairment or end-stage renal disease (ESRD), making it far safer than morphine or oxycodone in patients with declining renal function.

Schedule III Classification: Possesses lower federal scheduling (Schedule III) than full agonists (Schedule II), facilitating routine e-prescribing and refills where clinically appropriate.

4. Interventional Modalities

Interventional modalities interrupt nociceptive transmission along specific neuroanatomical structures, serving as key opioid-sparing techniques: Interventional Pain Strategies by Target Anatomy:

  • [Radicular Spine Pain] ──> Epidural Steroid Injections (ESI) (Transforaminal / Interlaminar)
  • [Facetogenic Axial Pain] ──> Medial Branch Blocks (MBB) followed by Radiofrequency Ablation (RFA)
  • [Peripheral Joint Pain] ──> Genicular / Suprascapular Nerve Blocks & Viscosupplementation
  • [Refractory Neuropathy] ──> Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) Lead Placement

Epidural Steroid Injections (ESIs): Targeted delivery of corticosteroids (e.g., dexamethasone, triamcinolone) into the epidural space adjacent to inflamed nerve roots for acute lumbosacral or cervical radiculopathy. ESIs reduce phospholipase A2 activity and blunt local inflammatory cytokines.

Facet Joint Denervation (Radiofrequency Ablation - RFA): For axial spinal pain stemming from facet arthropathy. Clinicians first confirm diagnostic relief via dual medial branch nerve blocks with local anesthetic; patients with ≥80% acute relief proceed to thermal RFA, which coagulates sensory innervation, providing 6 to 12+ months of pain relief.

Neuromodulation (Spinal Cord Stimulation - SCS): Implantation of epidural leads delivering electrical impulses to the dorsal columns, recruiting large A-beta fibers to inhibit nociceptive transmission (Melzack and Wall's gate control theory). Indicated for failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), and intractable diabetic neuropathy.